“They put an IV in your arm, and the first medicine that goes through puts you to sleep. And the second one stops all body functions,” Hendrix said. “They have some kind of button on the IV. You have ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Patients with vs without rheumatoid arthritis (RA), especially those with RA-associated interstitial lung disease (RA-ILD), have a significantly higher risk of developing lung cancer, according to ...

The following is a summary of “Evaluating sensitization-associated, neuropathic-like symptoms and psychological factors in ...

Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic ...

IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...

Patients with vs without keloids had a higher prevalence of interstitial lung disease after controlling for patient specific factors.

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a ...

Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.

Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell ...